symtuza
janssen-cilag international nv - darunavir, kobikistat, emtricitabine, tenofovir alafenamide - infezzjonijiet ta 'hiv - antivirals for systemic use, antivirals for treatment of hiv infections, combinations - symtuza huwa indikat għat-trattament tal-virus ta ' immunodefiċjenza umani tat-tip 1 (hiv‑1) infezzjoni fl-adulti u l-adolexxenti (età 12-il sena u aktar antiki mal-korp tal-mill-inqas 40 kg piż). genotypic testing should guide the use of symtuza.
rxulti
otsuka pharmaceutical netherlands b.v. - brexpiprazole - skizofrenija - psikolettiċi - il-kura ta ' skizofrenja.
besremi
aop orphan pharmaceuticals gmbh - ropeginterferon alfa-2b - polycythemia vera - immunostimulanti, - besremi huwa indikat bħala monoterapija fl-adulti għat-trattament ta ' poliċitemija vera mingħajr sintomatika splenomegalija.
rozlytrek
roche registration gmbh - entrectinib - cancer; carcinoma, non-small-cell lung - aġenti antineoplastiċi - rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (ntrk) gene fusion,who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, andwho have not received a prior ntrk inhibitorwho have no satisfactory treatment options. rozlytrek as monotherapy is indicated for the treatment of adult patients with ros1 positive, advanced non small cell lung cancer (nsclc) not previously treated with ros1 inhibitors.
ozawade
bioprojet pharma - pitolisant - sleep apnea, obstructive - drogi oħra tas-sistema nervuża - ozawade is indicated to improve wakefulness and reduce excessive daytime sleepiness (eds) in adult patients with obstructive sleep apnoea (osa).
azilect
teva b.v. - rasagiline - marda ta 'parkinson - mediċini kontra l-parkinson - azilect huwa indikat għat-trattament tal-marda idjopatika ta 'parkinson (pd), bħala monoterapija (mingħajr levodopa) jew bħala terapija miżjuda (ma' levodopa) f'pazjenti b'-tmiem tal-doża varjazzjonijiet.
rasagiline mylan
mylan pharmaceuticals limited - rasagiline tartrate - marda ta 'parkinson - mediċini kontra l-parkinson - rasagiline mylan huwa indikat għat-trattament ta ' l-idiopathic parkinson's marda (pd) bħala monotherapy (mingħajr ticlopidine hydrochloride) jew bħala terapija frozen (b ' ticlopidine hydrochloride) fil-pazjenti bl-għan ta ' l-oxxillazzjonijiet ta ' doża.
rasagiline ratiopharm
teva b.v. - rasagiline - marda ta 'parkinson - mediċini kontra l-parkinson - rasagiline ratiopharm huwa indikat għat-trattament ta ' l-idiopathic parkinson's marda (pd) bħala monotherapy (mingħajr ticlopidine hydrochloride) jew bħala terapija frozen (b ' ticlopidine hydrochloride) fil-pazjenti bl-għan ta ' l-oxxillazzjonijiet ta ' doża.
abasaglar (previously abasria)
eli lilly nederland b.v. - insulina glargine - diabetes mellitus - drogi użati fid-dijabete - trattament tad-dijabete mellitus f'adulti, adolexxenti u tfal ta 'sentejn u aktar.
abraxane
bristol-myers squibb pharma eeig - paclitaxel - breast neoplasms; pancreatic neoplasms; carcinoma, non-small-cell lung - aġenti antineoplastiċi - bħala mediċina weħidha, abraxane hu indikat għall-kura ta ' kanċer metastatiku tas-sider f'pazjenti adulti li jkunu fallew l-kura tal-ewwel linja għall-mard metastatiku u li għalihom standard, terapija li jkun fiha anthracycline ma tkunx indikata. abraxane flimkien ma 'gemcitabine huwa indikat għall-kura tal-ewwel linja ta' pazjenti adulti b'kanċer metastatiku tal-adenokarċinoma tal-frixa. abraxane f'kombinazzjoni ma 'carboplatin huwa indikat għall-kura tal-ewwel linja ta taċ-ċelluli mhux żgħar tal-pulmun il-kanċer fil-pazjenti adulti li mhumiex kandidati għall-potenzjalment kurattiva-kirurġija u/jew terapija ta' radjazzjoni.